Gemini Therapeutics Signs a Research Agreement with SERI to Identify New Therapies for Age-related Macular Degeneration

 Gemini Therapeutics Signs a Research Agreement with SERI to Identify New Therapies for Age-related Macular Degeneration

Gemini Therapeutics Signs a Research Agreement with SERI to Identify New Therapies for Age-related Macular Degeneration

Shots:

  • SERI and Gemini will investigate the link b/w genetic & potential biomarkers in patients with PCV. The collaboration leverages Gemini’s experience of precision medicine to develop therapies targeting the genetically defined patients
  • The agreement explores the molecular impact of specific genes linked to PCV which provide information in designing new therapies in future
  • Gemini is currently working on GEM103, a recombinant Complement Factor H therapy for dry AMD which the initiation point to develop therapies targeting the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Acrofan

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post